Related Experiment Videos
Amyotrophic lateral sclerosis: progress and prospects for treatment
1Laboratoire Aventis, Paris, France. michel.dib@aventis.com
Drugs
|January 22, 2003
Summary
Excitotoxic damage is implicated in amyotrophic lateral sclerosis (ALS) pathology. While riluzole offers some benefit, new treatments are needed, highlighting the importance of transgenic mouse models for drug discovery.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Amyotrophic lateral sclerosis (ALS) pathology involves excitotoxic damage.
- Abnormal superoxide dismutase (SOD) mutations are linked to familial ALS.
- Riluzole is the only approved treatment, slowing disease progression.
Purpose of the Study:
- To review the role of excitotoxicity and genetic factors in ALS.
- To evaluate the utility of transgenic mouse models in ALS research.
- To discuss the challenges and future directions for ALS clinical trials.
Main Methods:
- Review of scientific literature on ALS pathology and treatments.
- Analysis of data from transgenic mouse models expressing mutant SOD.
- Examination of outcomes from recent large-scale ALS clinical trials.
Main Results:
- Transgenic mouse models exhibit motor neurone disease, responsive to riluzole.
- Studies in mice suggest roles for excitotoxic, apoptotic, and oxidative stress.
- Recent large clinical trials, except for riluzole, have yielded disappointing results.
Conclusions:
- Transgenic mouse models are valuable for screening potential ALS therapies.
- Despite advances, effective treatments beyond riluzole remain elusive.
- Development of surrogate markers is crucial for efficient clinical trial screening.